Mounib Elchebly

Mounib Elchebly

Auto-generated profile, based on publicly available information

Mounib Elchebly

Lady Davis Institute for Medical Research, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
SJSanne Marlijn Janssen
Sanne Marlijn Janssen
RMRoy Moscona
Roy Moscona
MEMounib Elchebly
Mounib Elchebly
APAndreas Ioannis Papadakis
Andreas Ioannis Papadakis
MRMargaret Redpath
Margaret Redpath
Alan SpatzAlan Spatz
Alan Spatz
Melanoma is among the most aggressive cancers due to its tendency to metastasize early. Phenotype switching between a proliferative and an invasive state has been suggested as a critical process for metastasis, though the mechanisms that regulate state transitions are complex and remain poorly understood. Brother of Regulator of Imprinted Sites (BORIS), also known as CCCTC binding factor-Like (CTCFL), is a transcriptional modulator that becomes aberrantly expressed in melanoma. Yet, the role of BORIS in melanoma remains elusive. Here, we show that BORIS is involved in melanoma phenotype switching. Genetic modification of BORIS expression in melanoma cells combined with whole-transcriptome analysis indicated that BORIS expression contributes to an invasion-associated transcriptome. In line with these findings, inducible BORIS overexpression in melanoma cells reduced proliferation and increased migration and invasion, demonstrating that the transcriptional switch is accompanied by a phenotypic switch. Mechanistically, we reveal that BORIS binds near the promoter of transforming growth factor-beta 1 (TFGB1), a well-recognized factor involved in the transition towards an invasive state, which coincided with increased expression of TGFB1. Overall, our study indicates a pro-invasive role for BORIS in melanoma via transcriptional reprogramming.

1 July 2006 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
MCMélanie J. Chagnon
Mélanie J. Chagnon
MEMounib Elchebly
Mounib Elchebly
NUNoriko Uetani
Noriko Uetani
LDLuce Dombrowski
Luce Dombrowski
ACAlan Cheng
Alan Cheng
MTMichel Tremblay
Michel Tremblay
Several protein tyrosine phosphatases (PTPs) expressed in insulin sensitive-tissues are proposed to attenuate insulin action and could act as key regulators of the insulin receptor (IR) signaling pathway. Among these PTPs, RPTPσ is expressed in relatively high levels in insulin-target tissues. We show that RPTPσ−/− knockout mice have reduced plasma glucose and insulin concentrations in the fasted state compared with their wild-type siblings. The knockout animals were also more sensitive to exogenous insulin as assayed by insulin-tolerance tests. Despite increased whole-body insulin sensitivity, tyrosine phosphorylation of the IR was not increased in muscle of RPTPσ−/− animals, as would be expected in insulin-sensitive animals. Instead, the levels of IR tyrosine phosphorylation and PI3-kinase activity were reduced in the muscle of knockout animals stimulated with insulin in vivo. However, insulin-stimulated Akt serine phosphorylation was essentially identical between both groups of mice. Accordingly, muscles isolated from RPTPσ−/− mice did not have a significant increase in glucose uptake in response to insulin, suggesting that RPTPσ did not play a direct role in this process. Taken together, our results suggest an indirect modulation of the IR signaling pathways by RPTPσ. Since low dose injection of growth hormone (GH) normalized the response to exogenous insulin in RPTPσ−/− mice, we propose that the insulin hypersensitivity observed in RPTPσ−/− mice is secondary to their neuroendocrine dysplasia and GH/IGF-1 deficiency.

25 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SJSanne Marlijn Janssen
Sanne Marlijn Janssen
RMRoy Moscona
Roy Moscona
MEMounib Elchebly
Mounib Elchebly
APAndreas Ioannis Papadakis
Andreas Ioannis Papadakis
MRMargaret Redpath
Margaret Redpath
Alan SpatzAlan Spatz
Alan Spatz
Melanoma is among the most aggressive cancers due to its tendency to metastasize early. Phenotype switching between a proliferative and an invasive state has been suggested as a critical process for metastasis. The mechanisms that regulate these transitions are poorly understood, but are associated with transcriptional changes. Brother of Regulator of Imprinted Sites (BORIS), also known as CCCTC binding factor-Like (CTCFL), is a transcriptional modulator that becomes aberrantly expressed in melanoma. Here, we provide the first evidence that BORIS is involved in phenotype switching in melanoma. Genetic modification of BORIS expression in melanoma cells combined with whole transcriptome analysis indicated that BORIS expression contributes to an invasion-associated transcriptome. In agreement with this finding, inducible BORIS overexpression in melanoma cells reduced proliferation and increased migration and invasion, demonstrating that the transcriptional switch is accompanied by a phenotypic switch. Overall, our study indicates a pro-invasive role for BORIS in melanoma via transcriptional reprogramming.